{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:19:01Z","timestamp":1790266741484,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00280-018-3722-5","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T06:45:59Z","timestamp":1542350759000},"page":"27-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-4765","authenticated-orcid":false,"given":"Laure","family":"Deyme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Barbolosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4944-8063","authenticated-orcid":false,"given":"Florence","family":"Gattacceca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"3722_CR1","first-page":"13","volume":"14","author":"CH K\u00f6hne","year":"2000","unstructured":"K\u00f6hneCH, PetersGJ (2000) UFT: mechanism of drug action. Oncol Williston Park N14:13\u201318","journal-title":"Oncol Williston Park N"},{"key":"3722_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s10147-003-0330-z","volume":"8","author":"K Omura","year":"2003","unstructured":"OmuraK (2003) Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol8:132\u2013138. \n                    https:\/\/doi.org\/10.1007\/s10147-003-0330-z","journal-title":"Int J Clin Oncol"},{"key":"3722_CR3","first-page":"75","volume-title":"M\u00e9decine personnalis\u00e9e en canc\u00e9rologie digestive","author":"M Boisdron-Celle","year":"2013","unstructured":"Boisdron-CelleM, Gu\u00e9rin-MeyerV, CapitainO (2013) 5-fluorouracile: MSI, pharmacocin\u00e9tique, DPD, TYMS et MTHFR. In: M\u00e9decine personnalis\u00e9e en canc\u00e9rologie digestive. Springer, Paris, pp\u00a075\u201392"},{"key":"3722_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3747\/co.v18i1.708","volume":"18","author":"T Alcindor","year":"2011","unstructured":"AlcindorT, BeaugerN (2011) Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol18:18\u201325","journal-title":"Curr Oncol"},{"key":"3722_CR5","first-page":"1205","volume":"6","author":"MA Graham","year":"2000","unstructured":"GrahamMA, LockwoodGF, GreensladeD et al (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res6:1205\u20131218","journal-title":"Clin Cancer Res"},{"key":"3722_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1124\/dmd.32.5.505","volume":"32","author":"SP Sanghani","year":"2004","unstructured":"SanghaniSP, QuinneySK, FredenburgTB et al (2004) Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases Ces1a1, Ces2, and a newly expressed carboxylesterase isoenzyme, Ces3. Drug Metab Dispos32:505\u2013511. \n                    https:\/\/doi.org\/10.1124\/dmd.32.5.505","journal-title":"Drug Metab Dispos"},{"key":"3722_CR7","first-page":"2012","volume":"6","author":"A Santos","year":"2000","unstructured":"SantosA, ZanettaS, CresteilT et al (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res6:2012\u20132020","journal-title":"Clin Cancer Res"},{"key":"3722_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00003088-199733040-00001","volume":"33","author":"GG Chabot","year":"1997","unstructured":"ChabotGG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet33:245\u2013259. \n                    https:\/\/doi.org\/10.2165\/00003088-199733040-00001","journal-title":"Clin Pharmacokinet"},{"key":"3722_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/annonc\/mdg119","volume":"14","author":"M Ychou","year":"2003","unstructured":"YchouM, ConroyT, SeitzJF et al (2003) An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin\/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol14:481\u2013489. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdg119","journal-title":"Ann Oncol"},{"key":"3722_CR10","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"FalconeA, RicciS, BrunettiI et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nord ovest. J Clin Oncol25:1670\u20131676. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.09.0928","journal-title":"J Clin Oncol"},{"key":"3722_CR11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","volume":"23","author":"T Conroy","year":"2005","unstructured":"ConroyT, PaillotB, Fran\u00e7oisE et al (2005) Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer\u2014a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol Off J Am Soc Clin Oncol23:1228\u20131236. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.06.050","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3722_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"ConroyT, DesseigneF, YchouM et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med364:1817\u20131825","journal-title":"N Engl J Med"},{"key":"3722_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7010007","author":"S Thibodeau","year":"2018","unstructured":"ThibodeauS, VoutsadakisIA (2018) FOLFIRINOX chemotherapy in metastatic pancreatic cancer: a systematic review and meta-analysis of retrospective and phase II studies. J Clin Med. \n                    https:\/\/doi.org\/10.3390\/jcm7010007","journal-title":"J Clin Med"},{"key":"3722_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1200\/jco.2015.33.3_suppl.421","volume":"33","author":"M Alline","year":"2015","unstructured":"AllineM, ColomboPE, QuenetF et al (2015) Surgical resectability after neo-adjuvant FOLFIRINOX for borderline or locally advanced pancreatic adenocarcinoma. J Clin Oncol33:421\u2013421. \n                    https:\/\/doi.org\/10.1200\/jco.2015.33.3_suppl.421","journal-title":"J Clin Oncol"},{"key":"3722_CR15","unstructured":"ConroyT, HammelP, HebbarM et al (2018) Unicancer GI PRODIGE 24\/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. Meeting ASCO 2018. \n                    https:\/\/meetinglibrary.asco.org\/record\/159164\/abstract\n                    \n                  . Accessed 20 Jul 2018"},{"key":"3722_CR16","doi-asserted-by":"publisher","first-page":"9378","DOI":"10.3748\/wjg.v22.i42.9378","volume":"22","author":"J-F Guion-Dusserre","year":"2016","unstructured":"Guion-DusserreJ-F, BertautA, GhiringhelliF et al (2016) Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy. World J Gastroenterol22:9378\u20139386. \n                    https:\/\/doi.org\/10.3748\/wjg.v22.i42.9378","journal-title":"World J Gastroenterol"},{"key":"3722_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2217\/crc.12.20","volume":"1","author":"E Assenat","year":"2012","unstructured":"AssenatE (2012) FOLFIRINOX for the treatment of colorectal cancer: latest evidence from clinical trials. Colorectal Cancer1:181\u2013184. \n                    https:\/\/doi.org\/10.2217\/crc.12.20","journal-title":"Colorectal Cancer"},{"key":"3722_CR18","doi-asserted-by":"publisher","first-page":"82953","DOI":"10.18632\/oncotarget.12761","volume":"7","author":"J P\u00e9ron","year":"2016","unstructured":"P\u00e9ronJ, RoyP, ConroyT et al (2016) An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget7:82953","journal-title":"Oncotarget"},{"key":"3722_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/cam4.433","volume":"4","author":"RDW Marsh","year":"2015","unstructured":"MarshRDW, TalamontiMS, KatzMH, HermanJM (2015) Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med4:853\u2013863. \n                    https:\/\/doi.org\/10.1002\/cam4.433","journal-title":"Cancer Med"},{"issue":"1861","key":"3722_CR20","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.7150\/jca.16279","volume":"7","author":"SJ Rombouts","year":"2016","unstructured":"RomboutsSJ, MungroopTH, HeilmannMN et al (2016) FOLFIRINOX in locally advanced and metastatic pancreatic cancer: a single centre cohort study. J Cancer7(1861):1861\u20131866. \n                    https:\/\/doi.org\/10.7150\/jca.16279","journal-title":"J Cancer"},{"key":"3722_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1118\/1.598560","volume":"26","author":"J Kissel","year":"1999","unstructured":"KisselJ, PortRE, ZaersJ et al (1999) Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach. Med Phys26:609\u2013615. \n                    https:\/\/doi.org\/10.1118\/1.598560","journal-title":"Med Phys"},{"key":"3722_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","volume":"71","author":"F Mueller","year":"2013","unstructured":"MuellerF, B\u00fcchelB, K\u00f6berleD et al (2013) Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol71:361\u2013370. \n                    https:\/\/doi.org\/10.1007\/s00280-012-2018-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"3722_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1067\/mcp.2000.109352","volume":"68","author":"C Terret","year":"2000","unstructured":"TerretC, ErdociainE, GuimbaudR et al (2000) Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther68:270\u2013279. \n                    https:\/\/doi.org\/10.1067\/mcp.2000.109352","journal-title":"Clin Pharmacol Ther"},{"key":"3722_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/01.ftd.0000191305.64775.04","volume":"28","author":"Y Kho","year":"2006","unstructured":"KhoY, JansmanFGA, PrinsNH et al (2006) Population pharmacokinetics of oxaliplatin (85 mg\/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Ther Drug Monit28:206\u2013211. \n                    https:\/\/doi.org\/10.1097\/01.ftd.0000191305.64775.04","journal-title":"Ther Drug Monit"},{"key":"3722_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00280-002-0550-3","volume":"51","author":"J-P Delord","year":"2003","unstructured":"DelordJ-P, UmlilA, GuimbaudR et al (2003) Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol51:127\u2013131. \n                    https:\/\/doi.org\/10.1007\/s00280-002-0550-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"3722_CR26","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/00001813-200311000-00007","volume":"14","author":"G Bastian","year":"2003","unstructured":"BastianG, BarrailA, UrienS (2003) Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs14:817\u2013824. \n                    https:\/\/doi.org\/10.1097\/01.cad.0000099000.92896.5d","journal-title":"Anticancer Drugs"},{"key":"3722_CR27","first-page":"1613","volume":"18","author":"S Poujol","year":"2007","unstructured":"PoujolS, PinguetF, YchouM et al (2007) A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. Oncol Rep18:1613\u20131621","journal-title":"Oncol Rep"},{"key":"3722_CR28","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00280-008-0692-z","volume":"62","author":"PA Thompson","year":"2008","unstructured":"ThompsonPA, GuptaM, RosnerGL et al (2008) Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children\u2019s oncology group. Cancer Chemother Pharmacol62:1027\u20131037. \n                    https:\/\/doi.org\/10.1007\/s00280-008-0692-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"3722_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5414\/CPP48327","volume":"48","author":"T Kimura","year":"2010","unstructured":"KimuraT, KashiwaseS, MakimotoA et al (2010) Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors. Int J Clin Pharmacol Ther48:327\u2013334","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3722_CR30","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1002\/cncr.22241","volume":"107","author":"M Fouladi","year":"2006","unstructured":"FouladiM, BlaneySM, PoussaintTY et al (2006) Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors. Cancer107:2291\u20132297. \n                    https:\/\/doi.org\/10.1002\/cncr.22241","journal-title":"Cancer"},{"key":"3722_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pbc.22544","volume":"55","author":"O Beaty","year":"2010","unstructured":"BeatyO, BergS, BlaneyS et al (2010) A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a children\u2019s oncology group study. Pediatr Blood Cancer55:440\u2013445. \n                    https:\/\/doi.org\/10.1002\/pbc.22544","journal-title":"Pediatr Blood Cancer"},{"key":"3722_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00280-014-2667-6","volume":"75","author":"M Nikanjam","year":"2015","unstructured":"NikanjamM, StewartCF, TakimotoCH et al (2015) Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol75:495\u2013503. \n                    https:\/\/doi.org\/10.1007\/s00280-014-2667-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"3722_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s002800050980","volume":"44","author":"F Bressolle","year":"1999","unstructured":"BressolleF, JouliaJM, PinguetF et al (1999) Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol44:295\u2013302. \n                    https:\/\/doi.org\/10.1007\/s002800050980","journal-title":"Cancer Chemother Pharmacol"},{"key":"3722_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1191\/1078155204jp129oa","volume":"10","author":"B Porta-Oltra","year":"2004","unstructured":"Porta-OltraB, P\u00e9rez-RuixoJJ, Climente-Mart\u00edM et al (2004) Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients. J Oncol Pharm Pract10:155\u2013167. \n                    https:\/\/doi.org\/10.1191\/1078155204jp129oa","journal-title":"J Oncol Pharm Pract"},{"key":"3722_CR35","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2174\/156802612803531414","volume":"12","author":"C Woloch","year":"2012","unstructured":"WolochC, DiPaoloA, MarouaniH et al (2012) Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. Curr Top Med Chem12:1713\u20131719","journal-title":"Curr Top Med Chem"},{"key":"3722_CR36","doi-asserted-by":"publisher","first-page":"163174","DOI":"10.1007\/BF03257473","volume":"51","author":"ABP Kuilenburg van","year":"2012","unstructured":"vanKuilenburgABP, H\u00e4uslerP, SchalhornA et al (2012) Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a C.1905 + 1G>A Mutation in DPYD by means of a bayesian limited sampling strategy. Clin Pharmacokinet51:163\u2013174. \n                    https:\/\/doi.org\/10.1007\/BF03257473","journal-title":"Clin Pharmacokinet"},{"key":"3722_CR37","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/jcph.543","volume":"55","author":"AK Berg","year":"2015","unstructured":"BergAK, BucknerJC, GalanisE et al (2015) Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. J Clin Pharmacol55:1303\u20131312. \n                    https:\/\/doi.org\/10.1002\/jcph.543","journal-title":"J Clin Pharmacol"},{"key":"3722_CR38","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1067\/mcp.2002.129502","volume":"72","author":"CE Klein","year":"2002","unstructured":"KleinCE, GuptaE, ReidJM et al (2002) Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther72:638\u2013647. \n                    https:\/\/doi.org\/10.1067\/mcp.2002.129502","journal-title":"Clin Pharmacol Ther"},{"key":"3722_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.clpt.2004.03.008","volume":"76","author":"SP Joel","year":"2004","unstructured":"JoelSP, PapamichaelD, RichardsF et al (2004) Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. Clin Pharmacol Ther76:45\u201354. \n                    https:\/\/doi.org\/10.1016\/j.clpt.2004.03.008","journal-title":"Clin Pharmacol Ther"},{"key":"3722_CR40","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1200\/JCO.1999.17.6.1751","volume":"17","author":"E Wasserman","year":"1999","unstructured":"WassermanE, CuvierC, LokiecF et al (1999) Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol Off J Am Soc Clin Oncol17:1751\u20131759. \n                    https:\/\/doi.org\/10.1200\/JCO.1999.17.6.1751","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3722_CR41","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.1996.14.11.2959","volume":"14","author":"LB Saltz","year":"1996","unstructured":"SaltzLB, KanowitzJ, KemenyNE et al (1996) Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol14:2959\u20132967. \n                    https:\/\/doi.org\/10.1200\/JCO.1996.14.11.2959","journal-title":"J Clin Oncol"},{"key":"3722_CR42","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1100767","author":"S Kobuchi","year":"2015","unstructured":"KobuchiS, ItoY, NakanoY, SakaedaT (2015) Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats. Xenobiotica Fate Foreign Compd Biol Syst. \n                    https:\/\/doi.org\/10.3109\/00498254.2015.1100767","journal-title":"Xenobiotica Fate Foreign Compd Biol Syst"},{"key":"3722_CR43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/sj.bjc.6600447","volume":"87","author":"RHJ Mathijssen","year":"2002","unstructured":"MathijssenRHJ, VerweijJ, LoosWJ et al (2002) Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. Br J Cancer87:144\u2013150. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6600447","journal-title":"Br J Cancer"},{"key":"3722_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1208\/s12248-010-9249-2","volume":"13","author":"B Valenzuela","year":"2011","unstructured":"ValenzuelaB, Nalda-MolinaR, Bretcha-BoixP et al (2011) Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis. AAPS J13:72\u201382. \n                    https:\/\/doi.org\/10.1208\/s12248-010-9249-2","journal-title":"AAPS J"},{"key":"3722_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2017.02.010","volume":"76","author":"J-C Lee","year":"2017","unstructured":"LeeJ-C, KimJW, AhnS et al (2017) Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity. Eur J Cancer Oxf Engl 199076:125\u2013133. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.02.010","journal-title":"Eur J Cancer Oxf Engl 1990"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3722-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:19:07Z","timestamp":1573845547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3722-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3722"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3722-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"2 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal statement"}}]}}